Business

Marina Biotech (MRNA) Now Covered by Oppenheimer


Bank of America assumed coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd.


Morgan Stanley initiated coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd.


Piper Jaffray Companies initiated coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd.


Finally, JPMorgan Chase & Co. initiated coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd.


Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally.


The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.






Powered by Blogger.